Original Sky Meter Intranet
Highlights
A few days ago, Chengdu Women and Children's Central Hospital in Sichuan Province announced that it plans to publicly introduce 75 new drugs to meet the needs of clinical drugs, including 66 chemical drugs, 6 biological drugs and 3 Chinese patent medicines; Among them, exclusive varieties (including exclusive dosage forms) account for more than 30%, involving well-known pharmaceutical companies such as Yangtze River Pharmaceutical, China Resources Pharmaceutical, Winbond Pharmaceutical, and Roche.
Source: Official website of Chengdu Women's and Children's Central Hospital
According to the statistics of treatment categories, the drugs to be introduced by Chengdu Women's and Children's Central Hospital are mainly nervous system drugs, occupying 21 seats; Anti-tumor, immunomodulator, and dermatological drugs accounted for 8 and 7, respectively; There are 5 products each in the list of sensory system drugs, respiratory system drugs, digestive system and metabolic drugs, and cardiovascular and cerebrovascular system drugs.
Among the 75 drugs to be introduced, there are 23 exclusive varieties, accounting for more than one-third of the total; Among them, there are 16 chemical drugs, 4 biological drugs, and 3 Chinese patent medicines, involving Yangtze River Pharmaceutical's Shenquor Digestion Oral Liquid, China Resources Pharmaceutical's mitoxantrone hydrochloride injection for tracer, Chongqing Huabang Pharmaceutical's naftifen ketoconazole cream, and Sichuan Creed Pharmaceutical's Tanduspirone Citrate Capsule.
Shenqu Digestion Oral Liquid is a pediatric anorexia drug, which has the effect of eliminating food and strengthening the stomach, strengthening the spleen and regulating qi, and has been included in the national medical insurance class B drug list. In recent years, the terminal sales of the drug in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as China's public medical institutions) have increased year by year, and the harvest will exceed 270 million yuan in 2023, a year-on-year increase of 17.27%, making it the TOP3 product of pediatric anorexia Chinese patent medicine.
In 2023, it will be ranked TOP10 Chinese patent medicine products for pediatric anorexia in China's public medical institutions
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
Mitoxantrone hydrochloride injection for tracer was first approved for marketing in 2021 and is the first lymphatic tracer approved for thyroid cancer and breast cancer in China. In January 2023, the market achieved rapid expansion after the drug entered the medical insurance catalogue through negotiation, and the terminal sales of China's public medical institutions exceeded 50 million yuan in 2023, with a year-on-year growth rate of 771.14%. In addition, the latest clinical results show that mitoxantrone hydrochloride injection for tracer also has certain curative effects on lung cancer, melanoma, multiple myeloma, liver cancer, colorectal cancer, kidney cancer, prostate cancer and other cancers, and the product potential is gradually being released.
Sales trend of mitoxantrone hydrochloride injection for terminal tracing in China's public medical institutions in recent years (unit: 10,000 yuan)
Source: Minenet's competitive landscape of drug terminals in China's public medical institutions
Naffen ketoconazole cream is a topical antifungal drug, which is generally used for fungal infections caused by various causes such as tinea manis, tinea pedis, tinea corporis, and tinea versicolor. According to data from Minenet, at present, only one company of Chongqing Huabang Pharmaceutical has a production approval, and the terminal sales scale of China's public medical institutions will exceed 100 million yuan for the first time in 2023, an increase of more than 22% year-on-year, making it the TOP2 product of antifungal chemical drugs for skin diseases.
Source: One-click search on Minenet
In addition, the exclusive varieties to be admitted to the hospital also include Sinopharm Anhydrous Ethanol Injection, Shanghai Pharmaceutical's Sodium Isoambarbital for Injection, Sihuan Pharmaceutical's Midazolam Buccal Mucosal Solution, Shanxi Zhenglai Pharmaceutical's Ludangshen Oral Liquid, Roche's Pertuzumab Injection, etc., covering blood and hematopoietic system drugs, nervous system drugs, qi and blood replenishing drugs, anti-tumor and immunomodulators and other treatment categories, to further meet the clinical drug needs of different patients.
Procurement Catalogue of New Drugs to be Introduced (with * is an exclusive variety)
Source: Minenet database, Chengdu Women's and Children's Central Hospital
Note: The statistical scope of "Drug Terminal Competition Pattern of China's Public Medical Institutions" by Minenet is: China's urban public hospitals, county-level public hospitals, urban community centers and township health centers, excluding private hospitals, private clinics and village clinics; The above sales are calculated based on the average retail price of the product at the terminal. The statistics are as of May 17, if there is any omission, please correct!